Markets
ALT29073 (ALT29073)
ALT29073Stock
–
– (–) today
Last price
– 1D
- Market cap
- –
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- –
- Average volume
- –
- Previous close
- –
Analysts
4 coveringBuy3 buy, 1 hold, 0 sell
Targets a year out average $18.50
$17.00now –$20.00
Earnings
next estimate $-0.1600Next report
Dec 2025
-8.0%
Mar 2026
+28.0%
Jun 2026
+20.0%
Sep 2026
-7.1%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $26.0k | – | – | – |
| Gross profit | $26.0k | – | – | – |
| Operating income | -$28.89m | -$24.24m | -$26.23m | -$35.70m |
| Net income | -$27.36m | -$22.56m | -$22.82m | -$31.61m |
News
8 latest- ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding ConcernsZacks · 20 hours ago
- Altimmune, Inc. Reports Third Quarter 2026 Financial Results and $480 million in Cash and InvestmentsFintel · 1 day ago
- Altimmune (ALT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- What Altimmune (ALT) Said on Its Q3 Earnings CallMarketBeat · 1 day ago
- Altimmune, Inc. Draws $10.0 million Tranche Three Under Loan AgreementFintel · Oct 29, 2026
- Altimmune, Inc. Appoints Peter Greenleaf and Alex Howarth to Board of DirectorsFintel · Oct 27, 2026
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?Zacks · Oct 7, 2026
- Altimmune Details Pemvidutide’s Path Toward a Liver-Disease FranchiseMarketBeat · Oct 1, 2026
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.